BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
Having a healthy gut is key as it permits the body to build a stronger immune system
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
Cipla and Ethris partner for the development of mRNA-based therapies
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
Subscribe To Our Newsletter & Stay Updated
